The California STEM Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The California STEM Reporter.

Press releases published on October 25, 2026

3 hours ago

The Thread Consulting, LLC Led By Dr. Leonie H Mattison Named an OpenAI Select Partner

Indeterminate EIN Presswire

3 hours ago

Tomorrow, Today Releases Interview With Futurist Jorge Brown on AI, Polarization and the Next 50 Years

Indeterminate EIN Presswire

5 hours ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Indeterminate GlobeNewswire

6 hours ago

Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform

Indeterminate GlobeNewswire

8 hours ago

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Indeterminate GlobeNewswire

8 hours ago

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer …

Indeterminate GlobeNewswire

10 hours ago

Automating SEO and Link Building for AI Agents with Rapid Indexer's New MCP Server1

Indeterminate GlobeNewswire

10 hours ago

Unfair Links Launches a Link Building Service for Local Backlinks and Google Business Profile Matched Links

Indeterminate GlobeNewswire

10 hours ago

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Indeterminate GlobeNewswire

11 hours ago

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Indeterminate GlobeNewswire

13 hours ago

BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie

Indeterminate GlobeNewswire

13 hours ago

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Indeterminate GlobeNewswire